⚠ Official Notice: www.ijisrt.com is the official website of the International Journal of Innovative Science and Research Technology (IJISRT) Journal for research paper submission and publication. Please beware of fake or duplicate websites using the IJISRT name.



Early Locoregional Recurrence After Mastectomy for Triple-Negative Breast Cancer with Ipsilateral Axillary Lymph Node Involvement: A Case Report


Authors : Maha Lhaloui; Mustapha Benhessou; Simohamed Ennachit; Mohammed Elkerroumi

Volume/Issue : Volume 11 - 2026, Issue 6 - June

Google Scholar : https://tinyurl.com/3duwk765

Scribd : https://tinyurl.com/57hfe82h

DOI : https://doi.org/10.38124/ijisrt/26jun1809

PlumX Metrics

Semantic Scholar

ResearchGate

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Triple-negative breast cancers are defined by the absence of hormonal receptor expression (estrogen and progesterone) as well as the lack of HER2 overexpression. Their marked tendency toward early relapse, combined with pronounced clinical and biological aggressiveness, confers a high metastatic potential and significant resistance to conventional therapies. This complexity underscores the need for management strategies grounded in a comprehensive understanding of their molecular biology.

Keywords : Triple-Negative Breast Cancer, Chemotherapy, EGFR, PARP).

References :

  1. Azim HA, Partridge AH. Biology of breast cancer in young women. Breast Cancer Res 2014;16:427. http://dx.doi.org/10.1186/s13058-014-0427-5.
  2. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 2008;113:2638–45. http://dx.doi.org/10.1002/cncr.23930.
  3. Deluche E, Antoine A, Bachelot T, Lardy Cleaud A, Dieras V, Brain E, et al. Contem porary outcomes of metastatic breast cancer among 22,000 women from the multicenter ESME cohort 2008–2016. Eur J Cancer 2020;129:60–70. http://dx.doi.org/ 10.1016/j.ejca.2020.01.016.
  4. Herrera Juarez M ,Tolosa Ortega P , Sanchez de Torre   A , et al . Biology of the triple-negative breast cancer: immunohistochemical, RNA, and DNA features . Breast Care (Basel) 2020 ; 15 ( 3 ) : 208 – 16 .
  5. Foulkes WD , Smith IE ,Reis-Filho JS . Triple-negative breast cancer . N Engl J Med 2010 ; 363 ( 20 ) : 1938 – 48 .
  6. Gonçalves A , Bertucci A ,Bertucci F .PARP inhibitors in the treatment of early breast cancer: the step beyond? Cancers (Basel) 2020 ; 12 ( 6 ) : 1378 .
  7. Tome 4 > n86 > décembre 2023 10.1016/j.lpmfor.2023.10.019 © 2023 Elsevier Masson SAS. Tous droits réservés.
  8. Yang X, Song H, Leslie G, Engel C, Hahnen E, Auber B, et al. Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D. J Natl Cancer Inst 2020;112(12):1242–50.
  9. Hartmann LC, Lindor NM. The role of risk reducing surgery in hereditary breast and ovarian cancer. N Engl J Med 2016;374 (5):454–68.
  10. Thésaurus-Femmes porteuses d'une mutation de BRCA1 ou BRCA2/Détection précoce du cancer du sein et des annexes et stratégies de réduction du risque, Collection recommandations et référentiels, INCa, avril 2017.
  11. Banerjee S, Reis-Filho JS, Ashley S, Steele D, Ashworth A, Lakhani SR, et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol 2006;59:729–35.
  12. Abdulkarim BS, Cuartero J, Hanson J, Descheˆnes J, Lesniak D, Sabri S. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol 2011; 21:2852–8.
  13. Voduc KD, Cheang MCU, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and risk of local and regional relapse. J Clin Oncol 2010; 10:1684–91.
  14. Kyndi M, Sorensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J. Danish Breast Cancer Cooperative Group. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the danish breast cancer cooperative group. J Clin Oncol 2008;26(9):1419–26.
  15. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Time to disease recurrence in basal-type breast cancers. Cancer 2009;115(21):4917–23.
  16. Rodriguez-Pinilla S, Sarrio D, Honrado E, Hardisson D, Calero F, Benitez J, et al. Pronostic significance of basal-like phenotype and fascin expression in node negative invasive breast carcinomas. Clin Cancer Res 2006;12:1533–9.
  17. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. NEJM 2010;363:1938–48.

Triple-negative breast cancers are defined by the absence of hormonal receptor expression (estrogen and progesterone) as well as the lack of HER2 overexpression. Their marked tendency toward early relapse, combined with pronounced clinical and biological aggressiveness, confers a high metastatic potential and significant resistance to conventional therapies. This complexity underscores the need for management strategies grounded in a comprehensive understanding of their molecular biology.

Keywords : Triple-Negative Breast Cancer, Chemotherapy, EGFR, PARP).

Paper Submission Last Date
31 - July - 2026

SUBMIT YOUR PAPER CALL FOR PAPERS
Video Explanation for Published paper

Never miss an update from Papermashup

Get notified about the latest tutorials and downloads.

Subscribe by Email

Get alerts directly into your inbox after each post and stay updated.
Subscribe
OR

Subscribe by RSS

Add our RSS to your feedreader to get regular updates from us.
Subscribe